GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoVibronix Inc (NAS:NAOV) » Definitions » Cyclically Adjusted PS Ratio

NanoVibronix (NanoVibronix) Cyclically Adjusted PS Ratio : 0.53 (As of May. 15, 2024)


View and export this data going back to 2015. Start your Free Trial

What is NanoVibronix Cyclically Adjusted PS Ratio?

As of today (2024-05-15), NanoVibronix's current share price is $0.7152. NanoVibronix's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $1.36. NanoVibronix's Cyclically Adjusted PS Ratio for today is 0.53.

The historical rank and industry rank for NanoVibronix's Cyclically Adjusted PS Ratio or its related term are showing as below:

NAOV' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.53   Med: 2.61   Max: 10.51
Current: 0.53

During the past years, NanoVibronix's highest Cyclically Adjusted PS Ratio was 10.51. The lowest was 0.53. And the median was 2.61.

NAOV's Cyclically Adjusted PS Ratio is ranked better than
84.21% of 475 companies
in the Medical Devices & Instruments industry
Industry Median: 2.18 vs NAOV: 0.53

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

NanoVibronix's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.599. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.36 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


NanoVibronix Cyclically Adjusted PS Ratio Historical Data

The historical data trend for NanoVibronix's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NanoVibronix Cyclically Adjusted PS Ratio Chart

NanoVibronix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 3.81 0.85

NanoVibronix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.81 2.62 2.63 1.50 0.85

Competitive Comparison of NanoVibronix's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, NanoVibronix's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NanoVibronix's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NanoVibronix's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where NanoVibronix's Cyclically Adjusted PS Ratio falls into.



NanoVibronix Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

NanoVibronix's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.7152/1.36
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NanoVibronix's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, NanoVibronix's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.599/129.4194*129.4194
=0.599

Current CPI (Dec. 2023) = 129.4194.

NanoVibronix Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.473 99.695 0.614
201406 0.489 100.560 0.629
201409 0.191 100.428 0.246
201412 0.397 99.070 0.519
201503 0.221 99.621 0.287
201506 0.185 100.684 0.238
201509 0.175 100.392 0.226
201512 0.170 99.792 0.220
201603 0.249 100.470 0.321
201606 0.271 101.688 0.345
201609 0.266 101.861 0.338
201612 0.214 101.863 0.272
201703 0.227 102.862 0.286
201706 0.226 103.349 0.283
201709 0.284 104.136 0.353
201712 0.230 104.011 0.286
201803 0.240 105.290 0.295
201806 0.411 106.317 0.500
201809 0.168 106.507 0.204
201812 0.166 105.998 0.203
201903 0.237 107.251 0.286
201906 0.776 108.070 0.929
201909 0.286 108.329 0.342
201912 0.269 108.420 0.321
202003 0.314 108.902 0.373
202006 0.741 108.767 0.882
202009 0.321 109.815 0.378
202012 0.085 109.897 0.100
202103 0.085 111.754 0.098
202106 0.257 114.631 0.290
202109 0.382 115.734 0.427
202112 0.605 117.630 0.666
202203 0.194 121.301 0.207
202206 0.346 125.017 0.358
202209 0.069 125.227 0.071
202212 -0.069 125.222 -0.071
202303 0.214 127.348 0.217
202306 0.177 128.729 0.178
202309 0.266 129.860 0.265
202312 0.599 129.419 0.599

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NanoVibronix  (NAS:NAOV) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


NanoVibronix Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of NanoVibronix's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NanoVibronix (NanoVibronix) Business Description

Traded in Other Exchanges
Address
525 Executive Boulevard, Elmsford, New York, NY, USA, 10523
NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low frequency, low intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.
Executives
Christopher M Fashek director 8023 VANTAGE DR, SAN ANTONIO TX 78230
Stephen Russell Brown officer: Chief Financial Officer 18-B NEIL COURT, OCEANSIDE NY 11572
Aurora Cassirer director C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Maria Schroeder director C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Brian M Murphy director, officer: Chief Executive Officer 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Michael Ferguson director 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Thomas Mika director TEGAL CORP, 2201 SOUTH MCDOWELL BLVD, PETALUMA CA 94954
Ira A Greenstein director IDT CORP, 520 BROAD STREET, NEWARK NJ 07102
Harold Jacob director, officer: Chief Medical Officer HAADMUR MEBUYON 26, HARNOT, JERUSALEM L3 95403
Martin M Goldstein director C/O NANOVIBRONIX, INC., 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
William Stern director, officer: Chief Executive Officer 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Jona Zumeris director, officer: VP of Technology 105 MAXESS ROAD, SUITE S124, MELVILLE NY 11747
Miriam W Kelly 10 percent owner P.O. BOX 1443, BROOKLANDVILLE MD 21022